期刊
FUTURE ONCOLOGY
卷 19, 期 12, 页码 819-828出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-1131
关键词
androgen receptor inhibitor; castration-resistant prostate cancer; darolutamide; metastasis-free survival; nonmetastatic; prostate-specific antigen; PSA progression; Spain; Spanish
类别
In the Phase III ARAMIS study, darolutamide significantly prolonged metastasis-free survival in patients with high-risk nonmetastatic castration-resistant prostate cancer. In this post hoc analysis, Spanish participants treated with darolutamide had a longer metastasis-free survival compared to those treated with placebo, with similar treatment-emergent adverse events.
Aim: Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes in Spanish participants in ARAMIS. Patients & methods: Patients with high-risk nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide 600 mg twice daily or placebo, plus androgen-deprivation therapy. The primary end point was MFS. Descriptive statistics are reported for this post hoc analysis. Results: In Spanish participants, darolutamide (n = 75) prolonged MFS versus placebo (n = 42): hazard ratio 0.345, 95% confidence interval 0.175-0.681. The incidence and type of treatment-emergent adverse events were comparable between treatment arms. Conclusion: For Spanish participants in ARAMIS, efficacy outcomes favored darolutamide versus placebo, with a similar safety profile, consistent with the overall ARAMIS population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据